Anbio Biotechnology develops and commercializes in-vitro diagnostic (IVD) products across platforms such as lateral-flow immunoassays, molecular assays, and other laboratory and point-of-care formats. The company targets decentralized, rapid testing for labs, clinics, wellness channels, and at-home use, aiming to make diagnostics more accessible and affordable. Its revenue base has been weighted toward infectious-disease rapid tests while it expands into broader clinical areas including oncology and cardiovascular applications.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 23.5 | — | 10 | — |
| 2023 | 6.7 | -71.5% | 2.3 | -77.5% |
| 2024 | 8.2 | 21.9% | 2.4 | 5.3% |
| 2025 | 8.7 | 5.6% | 6.4 | 169.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Andretti Acquisition Corp. II (POLE), Range Capital Acquisition Corp II (RNGT), Jack in the Box Inc. (JACK), Repay Holdings Corporation (RPAY), Texas Ventures Acquisition III Corp (TVA), Archimedes Tech SPAC Partners II Co. (ATII)